Suzanne L Topalian

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. pmc Workshop on immunotherapy combinations. Society for Immunotherapy of Cancer annual meeting Bethesda, November 3, 2011
    Ivan Martinez Forero
    Centro de Investigación Médica Aplicada, Universidad de Navarra, Avda Pio XII, 55, 31008 Pamplona, Spain
    J Transl Med 10:108. 2012
  2. pmc Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
    Suzanne L Topalian
    Department of Surgery, Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21287, USA
    Curr Opin Immunol 24:207-12. 2012
  3. pmc Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
    Suzanne L Topalian
    Department of Surgery, Johns Hopkins University School of Medicine and the Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21287, USA
    N Engl J Med 366:2443-54. 2012
  4. pmc Cancer immunotherapy comes of age
    Suzanne L Topalian
    Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA
    J Clin Oncol 29:4828-36. 2011
  5. pmc Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody
    Evan J Lipson
    Department of Oncology, Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21287, USA
    Clin Cancer Res 19:462-8. 2013
  6. doi Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates
    Julie R Brahmer
    Johns Hopkins University School of Medicine, and the Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA
    J Clin Oncol 28:3167-75. 2010
  7. pmc Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
    Julie R Brahmer
    Johns Hopkins University School of Medicine and the Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21231, USA
    N Engl J Med 366:2455-65. 2012
  8. pmc Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma
    Sofia Lyford-Pike
    Department of Otolaryngology Head and Neck Surgery, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA
    Cancer Res 73:1733-41. 2013
  9. pmc Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape
    Janis M Taube
    Department of Dermatology, Johns Hopkins Medical Institutions, Baltimore, MD 21287, USA
    Sci Transl Med 4:127ra37. 2012
  10. pmc Identification of tumor-associated, MHC class II-restricted phosphopeptides as targets for immunotherapy
    Florence R Depontieu
    Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Proc Natl Acad Sci U S A 106:12073-8. 2009

Collaborators

Detail Information

Publications10

  1. pmc Workshop on immunotherapy combinations. Society for Immunotherapy of Cancer annual meeting Bethesda, November 3, 2011
    Ivan Martinez Forero
    Centro de Investigación Médica Aplicada, Universidad de Navarra, Avda Pio XII, 55, 31008 Pamplona, Spain
    J Transl Med 10:108. 2012
    ..The general perception is that the road ahead of us is full of combination clinical trials which hopefully will bring clinical benefit to our cancer patients at a fast pace...
  2. pmc Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
    Suzanne L Topalian
    Department of Surgery, Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21287, USA
    Curr Opin Immunol 24:207-12. 2012
    ..Encouraging early clinical results using blocking agents against components of the PD-1 pathway have validated its importance as a target for cancer immunotherapy...
  3. pmc Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
    Suzanne L Topalian
    Department of Surgery, Johns Hopkins University School of Medicine and the Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21287, USA
    N Engl J Med 366:2443-54. 2012
    ..Blockade of programmed death 1 (PD-1), an inhibitory receptor expressed by T cells, can overcome immune resistance. We assessed the antitumor activity and safety of BMS-936558, an antibody that specifically blocks PD-1...
  4. pmc Cancer immunotherapy comes of age
    Suzanne L Topalian
    Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA
    J Clin Oncol 29:4828-36. 2011
    ..Unlike conventional cancer therapies, most immunotherapies are active and dynamic, capable of inducing immune memory to propagate a successful rebalancing of the equilibrium between tumor and host...
  5. pmc Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody
    Evan J Lipson
    Department of Oncology, Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21287, USA
    Clin Cancer Res 19:462-8. 2013
    ..Here, we provide long-term follow-up on three patients from that trial who sustained objective tumor regressions off therapy, and test the hypothesis that reinduction therapy for late tumor recurrence can be effective...
  6. doi Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates
    Julie R Brahmer
    Johns Hopkins University School of Medicine, and the Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA
    J Clin Oncol 28:3167-75. 2010
    ..This phase I study sought to determine the safety and tolerability of anti-PD-1 blockade in patients with treatment-refractory solid tumors and to preliminarily assess antitumor activity, pharmacodynamics, and immunologic correlates...
  7. pmc Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
    Julie R Brahmer
    Johns Hopkins University School of Medicine and the Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21231, USA
    N Engl J Med 366:2455-65. 2012
    ..Blockade of interactions between PD-1 and PD-L1 enhances immune function in vitro and mediates antitumor activity in preclinical models...
  8. pmc Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma
    Sofia Lyford-Pike
    Department of Otolaryngology Head and Neck Surgery, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA
    Cancer Res 73:1733-41. 2013
    ....
  9. pmc Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape
    Janis M Taube
    Department of Dermatology, Johns Hopkins Medical Institutions, Baltimore, MD 21287, USA
    Sci Transl Med 4:127ra37. 2012
    ..These observations suggest that therapies that block this pathway may benefit patients with B7-H1(+) tumors...
  10. pmc Identification of tumor-associated, MHC class II-restricted phosphopeptides as targets for immunotherapy
    Florence R Depontieu
    Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Proc Natl Acad Sci U S A 106:12073-8. 2009
    ..This previously undescribed demonstration of MHC II-restricted phosphopeptides recognizable by human CD4(+) T cells provides potential new targets for cancer immunotherapy...